Jump to content

Wikipedia:Articles for deletion/SENS-01

Add links
From Wikipedia, the free encyclopedia
The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.

The result was delete‎. Sandstein 22:03, 24 February 2025 (UTC)[reply]

SENS-01

[edit]

[Hide this box] New to Articles for deletion (AfD)? Read these primers!

SENS-01 (edit | talk | history | protect | delete | links | watch | logs | views) – (View log | edits since nomination)
(Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL)

Seems to lack notability, sources are database entries and press releases. Seems way too soon to have an article on this. Prod was removed because "AdisInsight articles are notably published in the literature when drugs are finally approved" but there is no guarantee at all that this drug will ever be approved of course, WP:CRYSTAL. Fram (talk) 09:58, 17 February 2025 (UTC)[reply]

  • Keep: The drug's AdisInsight page is one of the main sources for the page. An AdisInsight drug profile isn't a simple database entry but is a full article and review on the drug. It's just paywalled so you can't see it. If or when a given drug is approved however, the AdisInsight page will be published as a literature review in the journal Drugs with the title: "[Drug name]: First approval", like so: [1] (example). Hence, the AdisInsight source meets WP:RS as being reliable, independent, and in-depth, and the criteria for WP:N are satisfied. On that basis, the page should be kept. There is also no policy or consensus that only approved drugs are notable. – AlyInWikiWonderland (talk, contribs) 10:58, 17 February 2025 (UTC)[reply]
  • The current AdisInsight page and the finally published one (assuming it ever happens for this drug) are vastly different though, it's not as if "this" page will be published as "literature review". Fram (talk) 11:15, 17 February 2025 (UTC)[reply]
  • Delete. Too early for this drug candidate that has not yet reached clinical trials. There is no independent coverage of the drug, and its chemical structure remains undisclosed. AdisInsight can only summarize publicly available information, which, to date, is limited to press releases, the company's website, and security filings. The drug has not been mentioned in any peer-reviewed journal articles. Historically, only about 10% of preclinical drug candidates advance to clinical trials, and of those, only about 15% gain approval for human use.[1][2] Boghog (talk) 07:11, 19 February 2025 (UTC)[reply]

References

  1. ^ Kimmitt R, Vieira M (July 2020). Moon S, Bezruki A (eds.). "Time and Success Rate of Pharmaceutical R&D". Knowledge Portal on innovation and access to medicines.
  2. ^ "Pipeline Attrition Rate and Risk Mitigation". Umbrex.
The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Wikipedia:Articles_for_deletion/SENS-01&oldid=1277480327"